



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/783,675

02/16/2004

James Say

20786US01

7215

23446 7590 12/14/2010
MCANDREWS HELD & MALLOY, LTD
500 WEST MADISON STREET
SUITE 3400
CHICAGO, IL 60661

EXAMINER

LAU, TUNG S

ART UNIT

PAPER NUMBER

2857

MAIL DATE

DELIVERY MODE

12/14/2010

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/783,675	Applicant(s) SAY ET AL.	
	Examiner TUNG S. LAU	Art Unit 2857	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 07/16/2010.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 55-69 and 73 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 55-69 and 73 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 07/16/2010 has been entered.

Claim Rejections - 35 USC § 102

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 55-69 and 73 are rejected under 35 U.S.C. 102(b) as being anticipated by B. Aussedat, (A user-friendly method for calibrating a subcutaneous glucose sensor-based hypoglycaemic alarm, *Biosensors & Bioelectronics* Vol. 12. No. 11, pp. 1061–1071, 24 March 1997).

Regarding claim 55:

B. Aussedat describes a device for monitoring glucose concentration in a biological sample of a host (page 1061, ECU), the device comprising: a continuous glucose sensor that produces a data stream indicative of a glucose concentration in a host (page 1061, ECU glucose monitoring), the data stream

including a plurality of time spaced sensor data points (fig. 1); and an integrated receiver that receives the data stream from the continuous glucose sensor (page 1061, ECU), wherein the integrated receiver includes a single point glucose monitor (page 1062, needle type glucose sensor), a processor (page 1062, ECU), and a computer readable memory (page 1063, wearable ECU), wherein the single point glucose monitor is configured to receive a biological sample from the host and to measure the concentration of glucose in the sample ((page 1062, measure glucose concentration), the measured glucose concentration including a reference data point (fig. 1, max, min, etc), and wherein the computer readable memory includes instructions configured to cause the processor to process the data stream received from the continuous glucose sensor determine a rate of change of the data stream received from the continuous glucose analyte sensor and calibrate the data stream using the glucose concentration measured by the single point glucose monitor (page 1063-1064, monitor rate of change in fig. 1 to perform calibration).

Regarding claim 56, B. Aussedat further describes wherein the integrated receiver is configured to reject a reference data point obtained when the rate of change of the data stream is above a threshold (page 1062, ECU alarm when below or above threshold).

Regarding claim 57, B. Aussedat further describes wherein the integrated receiver includes a data matching module configured to match a reference data point to a sensor data point to form a matched data pair, wherein the reference

data point and the sensor data point are obtained at substantially corresponding times, and wherein the rate of change of the data stream is below a threshold at the time the sensor data point is obtained (fig. 1).

Regarding claim 58, B. Aussedat further describes wherein the integrated receiver includes a calibration module configured to form calibration information based at least in part on at least one reference data point and at least one sensor data point, wherein the reference data point and the sensor data point are obtained at substantially corresponding times (page 1063-1064), and wherein the rate of change of the data stream is below a threshold at the time the sensor data point is obtained (fig. 1, beep 2).

Regarding claim 59, B. Aussedat further describes wherein the integrated receiver includes a conversion function module configured to create a conversion function based at least in part on at least one sensor data point, wherein the sensor data point is obtained when the rate of change of the data stream is below a threshold, and wherein the conversion function is configured to convert the sensor data point into a calibrated data point (page 1063-1064, fig. 1, beep 2).

Regarding claim 60, B. Aussedat further describes wherein the integrated receiver includes a sensor data transformation module configured to convert at least one sensor data point into a calibrated data point, and wherein the rate of change of the data stream at the time at which the sensor data point is obtained is below a threshold (fig. 1).

Regarding claim 61, B. Aussedat further describes wherein the integrated receiver includes a calibration module configured to form a calibration set based at least in part on at least one matched data pair, the matched data pair including reference data point and a sensor data point (fig. 1), wherein the reference data point and the sensor data point are obtained at substantially corresponding times and wherein the integrated receiver includes a calibration evaluation module configured to evaluate the matched pair (fig. 1), wherein the calibration evaluation module is configured to prevent the matched data pair from influencing the calibration set if the rate of change of the data stream at the time the sensor data point is obtained is above a threshold (fig. 1, different data point).

Regarding claim 62, B. Aussedat further describes wherein the integrated receiver includes a clinical module configured to compare a first reference data point to a second reference data point to determine whether the first reference data point is clinically acceptable (page 1063-1064, below define threshold), wherein the second reference data point is obtained prior to obtaining the first reference data point, and wherein the first reference data point is determined to be clinically acceptable if the difference between the first reference data point and the second reference data point is below a threshold (page 1063-1064, below define threshold).

Regarding claim 63, B. Aussedat further describes wherein the integrated receiver includes a clinical module configured to compare a first sensor data point to a second sensor data point to determine whether the first sensor data

Art Unit: 2857

point is clinically acceptable, wherein the second sensor data point is obtained prior to obtaining the first sensor data point Page 1064-1065, fig. 1, 2), and wherein the first sensor data point is determined to be clinically acceptable if the difference between the first sensor data point and the second sensor data point is below a threshold (page 1063-1064. within threshold value)

Regarding claim 64, B. Aussedat further describes wherein the integrated receiver includes a stability module configured to determine whether the sensor data is stable, and wherein the sensor data is determined to be stable if the rate of change of the data stream is below a threshold at the time the sensor data is obtained (page 1063-1064m rate of change within threshold or not).

Regarding claim 65, B. Aussedat further describes measurements indicative of in vivo glucose concentration, and wherein the threshold is set at a predetermined level (page 1061-1062, in vivo and real time detection of glucose level).

Regarding claim 66, B. Aussedat further describes measurements indicative of in vivo glucose concentration (page 1063, in vivo), the threshold is 0.25 mg/dL/min (page 1065, can detect below 70 mg/dl/min, 0.25 is less than 70).

Regarding claim 67, B. Aussedat further describes wherein the data stream comprises measurements indicative of in vivo glucose concentration (page 1063, in vivo), and wherein the threshold is 0.5 mg/dL/min (page 1065, can detect below 70 mg/dl/min, 0.5 is less than 70).

Regarding claim 68, B. Aussedat further describes measurements indicative of in vivo glucose concentration (page 1061-1062), and wherein the threshold is greater than 0.5 mg/dL.min (page 1063, 70 mg/dl).

Regarding claim 69, B. Aussedat further describes wherein the integrated receiver includes an interface (page 1063, ECU with display), and wherein the user interface is configured to request additional reference data when the rate of change of the data stream is below a predetermined threshold (fig. 1, data below L2 region).

Regarding claim 73, B. Aussedat further describes wherein the integrated receiver includes an. interface configured to display continuous glucose sensor data and single point glucose monitor data (page 1062-1063, display LCD from ECU, with needle type as single point glucose monitor).

Contact information

3. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tung S. Lau whose telephone number is 571-272-2274. The examiner can normally be reached on M-F 9-5:30. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Drew Dunn can be reached on 571-272-2312. The fax phone numbers for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 2857

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Tung S. Lau/

Primary Examiner, Art Unit 2857

December 10, 2010